Phase IIB trial of neoadjuvant oral tamoxifen versus transdermal 4-hydroxytamoxifen in women with dcis of the breast
Ended Awarded Last action
- Contract number
- HHSN26100011
- Awardee
-
Northwestern University UEI KG76WYENL5K1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,159,347
Award facts
- Contract value 100% obligated
- $1,159,347.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Chicago, IL 60611, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1 | |
| Funding Only Action | -$289,532 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Exercise an Option | $111,986 | |
| Change Order | $0 | |
| Exercise an Option | $601,680 | |
| Change Order | $105,004 | |
| Original award | $630,210 |
About this award
This federal contract award, with a ceiling value of $1,159,347.10, was issued by the National Cancer Institute (NCI) to Northwestern University. The contract is part of the NCI's "Cancer Prevention Agent Development Program: Early Phase Clinical Research" and involves a Phase IIB clinical trial to evaluate the efficacy of topical 4-hydroxytamoxifen versus oral tamoxifen in treating ductal carcinoma in situ (DCIS) of the breast. Northwestern University is the prime contractor, and the study involves several subcontractors including Mayo Clinic, University of Kansas Medical Center Research Institute, Cleveland Clinic Lerner College of Medicine, Sloan-Kettering Institute for Cancer Research, Duke University, and St. Elizabeth Medical Center. This award was not set aside for any specific socioeconomic category. The study aims to demonstrate that topical 4-hydroxytamoxifen is not inferior to oral tamoxifen in reducing the Ki-67 labeling index of DCIS lesions.
Quick answers
Who was awarded contract HHSN26100011?
HHSN26100011 was awarded to Northwestern University by National Cancer Institute (National Institutes of Health) on September 15, 2016.
How much is contract HHSN26100011 worth?
The government has obligated $1,159,347 on HHSN26100011.
Is contract HHSN26100011 an order under another contract?
Yes. HHSN26100011 is a delivery order under HHSN261201200035I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100011 competed?
The extent of competition for HHSN26100011 was full and open competition. The government received 6 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award